Trial
NCT01377389
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Bristol-Myers Squibb
Condition
Prostate Cancer
Intervention
Ipilimumab
Why stopped
Due to adverse events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-29